Winnipeg, Canada
Winnipeg, Canada

The University of Manitoba is a public university in the province of Manitoba, Canada. Located in Winnipeg, it is a research-intensive post-secondary educational institution. Founded in 1877, it was Western Canada’s first university. Wikipedia.


Time filter

Source Type

Patent
University of Manitoba | Date: 2014-12-17

A composition for therapy of a peripheral neuropathy disorder in a subject in need thereof. The composition comprises an effective amount of an agent selected from a group consisting of pirenzepine, oxybutynin, muscarinic toxin 7, a muscarinic receptor antagonist, and combinations thereof, and a pharmacologically acceptable carrier and/or an excipient. The composition is useful for therapy of peripheral neuropathies exemplified by peripheral neuropathies induced by systemic diseases, peripheral neuropathies induced by metabolic diseases, chemotherapy-induced peripheral neuropathies, compression-induced peripheral neuropathies, peripheral neuropathies induced by exposure to dichloroacetate, immune-mediated peripheral neuropathies, peripheral neuropathies induced by infections, and genetically acquired peripheral neuropathies.


Patent
University of Manitoba | Date: 2015-02-18

An enzymatic method is provided for restructuring an affinity ligand bound heterogenous glycoform antibody sample to a substantially homogenous single desired glycoform antibody sample for therapeutic uses and kits for performing the methods. A method for enzymatically altering the Fc region of an affinity ligand bound antibody from a heterogenous glycoform to a substantially homogenous single glycoform comprises: contacting the affinity ligand bound heterogeneous glycoform antibody with a reaction buffer designed for a particular glycoform modification for a time sufficient and under conditions to modify the glycoform of the Fc region to a substantially homogeneous single form; optionally adding one or more nucleotide sugars and/or cofactors; and releasing the substantially homogeneous single glycoform antibody sample from said affinity ligand. The invention also encompasses biopharmaceuticals comprising single glycoform mAbs and polyclonal antibodies enzymatically produced for the treatment of cancers and immune disorders as well as compositions comprising the single glycoform antibodies as a biopharmaceutical.


Patent
University of Manitoba | Date: 2016-09-28

The Mito-Ob obese mouse model overexpresses the mitochondrial protein prohibitin (PHB). Mito-Ob male mice develop insulin resistance in addition to obesity and they do not develop overt diabetes. It has been discovered that these mice also spontaneously develop nonalcoholic steatohepatitis (NASH) and hepatocarcinogenesis over time. Also described is a mutant Mito-Ob mouse that develops lymphadenopathy and histiocytosis.


A ventilator system for determining respiratory system resistance (R) comprising a flowmeter that measures the flow rate (V) and volume (V) of gas received by a patient;a pressure sensor that measures pressure near the airway of the patient (Paw); and electronic circuitry to receive the Paw, V and V signals and which is also connected to a control system of the ventilator, comprising : - circuitry to generate an output that results in a step decrease (negative pulse) in the pressure and/or flow output of the ventilator during selected inflation cycles;- circuitry to measure Paw, V and V at a point (To) near the beginning of the pulse, at a point (T_(i)) near the trough of the negative pulse, and at a point preceding To but after the onset of inspiratory effort; and- circuitry to calculate the value of resistance (R) based on the measured values.


Gentisic acid sodium salt is shown to be useful as a treatment to improve systemic hemodynamics, hepatic mitochondrial function and lactic acidemia in patients with septic shock.


A composition for treating or preventing a Th2-dysregulated inflammatory condition wherein the composition comprises a therapeutically effective amount of one or more IDR peptides. Use of IDR peptides or a composition comprising IDR peptides for treating or preventing a Th2-dysregulated inflammatory condition. The Th2-dysregulated inflammatory condition includes allergy or atopy, for example allergic asthma.


Patent
University of Manitoba | Date: 2016-12-28

An enzymatic method is provided for restructuring an affinity ligand bound heterogenous glycoform antibody sample to a substantially homogenous single desired glycoform antibody sample for therapeutic uses and kits for performing the methods. A method for enzymatically altering the Fc region of an affinity ligand bound antibody from a heterogenous glycoform to a substantially homogenous single glycoform comprises: contacting the affinity ligand bound heterogeneous glycoform antibody with a reaction buffer designed for a particular glycoform modification for a time sufficient and under conditions to modify the glycoform of the Fc region to a substantially homogeneous single form; optionally adding one or more nucleotide sugars and/or cofactors; and releasing the substantially homogeneous single glycoform antibody sample from said affinity ligand. The invention also encompasses biopharmaceuticals comprising single glycoform mAbs and polyclonal sntibodies enzymatically produced for the treatment of cancers and immune disorders as well as compositions comprising the single glycoform antibodies as a biopharmaceutical.


Patent
University of Manitoba | Date: 2015-07-07

Exemplary imaging systems, apparatus, and methods may include a plurality of reconfigurable antenna assemblies. The reconfigurable antenna assemblies may each include one or more antennas. The antennas may be configured in a plurality of states including a passive state in which the antenna may not perturb the electromagnetic field. The antennas may be positioned about a measurement domain such as, e.g., a conductive measurement chamber.


Power of reflected waves of a multi-port antenna apparatus is measured by connecting a circulator between the respective output of the multi-output feeding network and the multi-port antenna. Each circulator has a plurality of ports where the output signal from the network is communicated to a first port of through the circulator and from the second port of the circulator to the respective port of the multi-port antenna and such that the reflected waves from the respective port of the multi-port antenna are communicated back to the second port of the circulator and through the circulator to a third port of the circulator and measuring the reflected waves from a selected one of the ports of the multi-port antenna by connecting the third port of the respective circulator to a vector network analyzer while connecting each of the third ports of the remaining circulators to a standard matching load.


Bernstein C.N.,University of Manitoba
American Journal of Gastroenterology | Year: 2015

In assessing the best evidence for optimizing management of inflammatory bowel disease (IBD), the focus is typically on anti-inflammatory agents and therapies that modulate the immune system. The intestinal immune response remains the key focus of developing therapies as well. In the past decade, the concept of dysbiosis of the gut microbiome has emerged as a potential pathogenetic focus in IBD, and with this a burgeoning interest in manipulating the microbiome as a means of controlling the disease has emerged. In this review, anti-inflammatory, immune-modulating, and microbiome-modulating therapies will be covered in terms of what is known today, as well as treatments that may be part of the therapeutic armamentarium in the near future. Concurrent with the evolution of our understanding of the basic biology of IBD, there is an increasing appreciation for the disconnect between patients' symptoms and inflammatory disease. As clinical trials have simultaneously addressed both symptom scores and mucosal healing, investigators and clinicians have gained a greater appreciation for the fact that many symptoms may not be driven by active inflammation, and hence focusing only on immunomodulatory therapies would not serve patients' needs fully. Furthermore, there is an emerging recognition of the importance of stress and psychological health in symptom experience and treatment needs. In this review, approaches to managing patients' symptoms as well as other adjunctive approaches to improving well-being will also be discussed. Finally, throughout this review, important research questions regarding different aspects of treatment will be proposed. © 2015 by the American College of Gastroenterology.

Loading University of Manitoba collaborators
Loading University of Manitoba collaborators